» Articles » PMID: 9142380

Combined Intensive Chemotherapy and Radical Surgery for Incurable Gastric Cancer

Overview
Journal Ann Surg Oncol
Publisher Springer
Specialty Oncology
Date 1997 Apr 1
PMID 9142380
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Background: To improve the poor prognosis of patients with advanced incurable gastric cancer, intensive chemotherapy combined with radical surgery was used.

Patients And Methods: Thirty patients with incurable gastric cancer were treated with a combination of 5-fluorouracil (370 mg/m2) and leucovorin (30 mg/person), given intravenously for five consecutive days, followed by cisplatinum (70 mg/m2) and etoposide (70 mg/m2) on days 6 and 20, delivered through a catheter placed either in the aorta with its tip at the level of the ninth thoracic vertebra or in the celiac artery. This treatment (FLEP therapy) was repeated twice every 5 weeks. Radical or palliative surgery followed chemotherapy.

Results: The overall response rate to the chemotherapy was 50.0% (15 of 30 patients, 95% confidence limit 0.305-0.671). Nineteen patients (15 with a partial response, three showing no change, and one with progressive disease) underwent surgery. Of these, nine underwent curative surgery and 10 palliative surgery. The median survival time was 6.5 months overall, 12.7 months for responders, and 4.7 months for nonresponders. Long-term survivors were exclusively found among patients with distant lymph node metastasis treated by curative surgery (55.6% at 5 years).

Conclusions: Favorable results of this small phase II study justify a phase III trial.

Citing Articles

Emerging Trends in the Management of Gastric Malignancy with Peritoneal Dissemination: Same Disease, Heterogeneous Prognosis.

Mela E, Theodorou A, Kimpizi D, Konstantinou K, Belimezakis N, Schizas D Cancers (Basel). 2025; 17(1.

PMID: 39796744 PMC: 11719794. DOI: 10.3390/cancers17010117.


Analysis of the therapeutic effect and influencing factors on unresectable gastric cancer treated with conversion therapy.

Han S, Han S, Qian J, Guo M, Fan J Front Oncol. 2024; 14:1435398.

PMID: 39540147 PMC: 11557377. DOI: 10.3389/fonc.2024.1435398.


Pathological Complete Response Achieved with XELOX Chemotherapy, HIPEC, and Anti-PD-1 Immunotherapy in Stage IV Gastric Adenocarcinoma with Peritoneal Metastasis: A Case Report and Review of the Literature.

Zhou J, Wang J, Wang W, Sun L, Zhao S, Sun Q J Gastrointest Cancer. 2024; 55(3):1441-1447.

PMID: 38676903 DOI: 10.1007/s12029-024-01056-0.


Palliative Gastrectomy Improves the Survival of Patients with Metastatic Early-Onset Gastric Cancer: A Retrospective Cohort Study.

An H, Wang P, Liu Y Curr Oncol. 2023; 30(9):7874-7890.

PMID: 37754487 PMC: 10527682. DOI: 10.3390/curroncol30090572.


Human epidermal growth factor 2 overexpressed alpha-fetoprotein-producing-gastric cancer.

Shimizu H, Kochi M, Fujii M, Watabe M, Matsuno Y, Kawai T Discov Oncol. 2023; 14(1):111.

PMID: 37354221 PMC: 10290623. DOI: 10.1007/s12672-023-00731-1.